<p>Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:</p>

<ul>
	<li>As a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.</li>
	<li>In combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.</li>
	<li>In combination with docetaxel, for treatment of metastatic non-small&nbsp;cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Ramucirumab.</li>
	<li>In combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.</li>
	<li>As a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha-fetoprotein of &ge;400 ng/mL and have been treated with sorafenib.</li>
</ul>